View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 19, 2018

US researchers license new catheter technology to HoliStick Medical

Harvard University in the US has out-licensed a new surgical catheter technology to French start-up HoliStick Medical for further development and commercialisation.

Harvard University in the US has out licensed a new surgical catheter technology to French start up HoliStick Medical for further development and commercialisation .

Harvard co owns this medical technology with Brigham & amp ; Women s Hospital , Boston Children s Hospital and Massachusetts Institute of Technology ( MIT ).

Under the agreement signed between Harvard s Office of Technology Development ( OTD ) and HoliStick , the latter gets exclusive worldwide rights to commercially develop the new surgical device .

The minimally invasive device was developed by a team of bioengineers and clinicians led by Harvard John A Paulson School of Engineering and Applied Sciences ( SEAS ) professor Conor Walsh and doctoral student Ellen Roche .

It has been designed to repair holes in the heart and tissue defects in other organs by using flexible , deployable soft structures such as patches and eliminates the need for sutures or rigid products . < div class =” rightpullquote “>” The researchers hope that over time the device can help in offering lasting repair for certain organ defects , including a hole in the heart .” div > Walsh said : “ Ellen s brilliant leadership of this project and the essential input of our engineering and clinical colleagues have resulted in the creation of a less invasive , less traumatic device that could really improve the way difficult tissue repairs are performed and , hopefully , reduce the need for procedures like open heart surgery .”

The researchers hope that over time the device can help in offering lasting repair for certain organ defects , including a hole in the heart , without the challenges or risks associated with existing more invasive surgical procedures .

Harvard OTD Strategic Partnerships executive director Sam Liss said : “ To carry an early stage medical technology into clinical application requires both commitment and strategic sophistication .

We re thrilled to see this technology enter commercial development in the hands of a well resourced startup that shares our vision of advancing innovation to transform patient care worldwide .”

HoliStick is supported by French venture capital company Truffle Capital that has $ 1 . 2bn in assets under management .

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network